Characterization of smoke and aerosol deliveries from combustible cigarettes, heated tobacco products and electronic nicotine delivery systems in the Vitrocell® Mammalian 6/48 exposure module.
Nonclinical
Chemical
Analysis
Keyser (2022)
Part two: an unblinded, parallel, randomized study to assess nicotine pharmacokinetics of four Vuse Solo ENDS flavors in smokers.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Keyser (2023)
Tracing the movement of electronic cigarette flavor chemicals and nicotine from refill fluids to aerosol, lungs, exhale, and the environment.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Khachatoorian (2022)
E-cigarette aerosol induced cytotoxicity, DNa damages and late apoptosis in dynamically exposed a549 cells.
Nonclinical
Cytotoxicity
Khalil (2021)
Flavoring Compounds Dominate Toxic aldehyde Production during E-Cigarette Vaping
Non-Clinical
Respiratory Toxicity
In Vitro
khlystov and samburova (2016)
associations between reasons for vaping and current vaping and smoking status: Evidence from a UK based cohort.
Population Clinical
Consumer Use
Reasons For Use
Khouja (2020)
association between e-cigarette use and sleep deprivation in U.S. Young adults: Results from the 2017 and 2018 Behavioral Risk Factor Surveillance System.
Individual Clinical
Safety
Adverse Effects
Kianersi (2021)
Daily Cigarette Consumption and Urine Cotinine Level between Dual Users of Electronic and Conventional Cigarettes, and Cigarette-Only Users.
Individual Clinical
Biomarkers
Biomarkers Of Exposure
Kim (2020)
Electronic cigarettes may not be a “safer alternative” of conventional cigarettes during pregnancy: evidence from the nationally representative PRaMS data.
Population Clinical
Population Health Impact
Kim (2020)
Modeling Electronic-Cigarette Users’ Risk Information avoidance.
Population Clinical
Perception Of Risk
Kim (2022)